Crossref
EE60 COST-EFFECTIVENESS OF TRIFLURIDINE/TIPIRACIL PLUS BEVACIZUMAB VERSUS REGORAFENIB IN REFRACTORY METASTATIC COLORECTAL CANCER IN KAZAKHSTAN
Value in Health · 2026-06 · 29 (6) · S74
DOI: 10.1016/j.jval.2026.03.355 ↗Kurz gefasst
Fachartikel in der Zeitschrift Value in Health, 2026-06. Verfasst von Talgat S. Nurgozhin und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Nurgozhin, T. S., Sergazy, S., Almadiyeva, A., Kostyuk, A., & Ramil, A. (2026). EE60 COST-EFFECTIVENESS OF TRIFLURIDINE/TIPIRACIL PLUS BEVACIZUMAB VERSUS REGORAFENIB IN REFRACTORY METASTATIC COLORECTAL CANCER IN KAZAKHSTAN. Value in Health, 29(6), S74. https://doi.org/10.1016/j.jval.2026.03.355
Vancouver
Nurgozhin TS, Sergazy S, Almadiyeva A, Kostyuk A, Ramil A. EE60 COST-EFFECTIVENESS OF TRIFLURIDINE/TIPIRACIL PLUS BEVACIZUMAB VERSUS REGORAFENIB IN REFRACTORY METASTATIC COLORECTAL CANCER IN KAZAKHSTAN. Value in Health. 2026;29(6):S74. doi:10.1016/j.jval.2026.03.355
BibTeX
@article{Nurgozhin2026,
author = {Nurgozhin, Talgat S. and Sergazy, Shynggys and Almadiyeva, Alima and Kostyuk, Alexander and Ramil, Abrakhmanov},
title = {EE60 COST-EFFECTIVENESS OF TRIFLURIDINE/TIPIRACIL PLUS BEVACIZUMAB VERSUS REGORAFENIB IN REFRACTORY METASTATIC COLORECTAL CANCER IN KAZAKHSTAN},
journal = {Value in Health},
year = {2026},
volume = {29},
number = {6},
pages = {S74},
doi = {10.1016/j.jval.2026.03.355}
}
EUVIMED